Michael T.  Constantino net worth and biography

Michael Constantino Biography and Net Worth

Director of Humacyte
Mr. Constantino is a retired Ernst & Young LLP assurance partner who served in the Research Triangle Park region of North Carolina for over 30 years. Mr. Constantino holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina Certified Public Accountant, or CPA. Mr. Constantino is serves as Chair of Humacyte’s Audit Committee.

What is Michael T. Constantino's net worth?

The estimated net worth of Michael T. Constantino is at least $17,550.00 as of May 23rd, 2022. Mr. Constantino owns 4,500 shares of Humacyte stock worth more than $17,550 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Constantino may own. Learn More about Michael T. Constantino's net worth.

How do I contact Michael T. Constantino?

The corporate mailing address for Mr. Constantino and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected]. Learn More on Michael T. Constantino's contact information.

Has Michael T. Constantino been buying or selling shares of Humacyte?

Michael T. Constantino has not been actively trading shares of Humacyte over the course of the past ninety days. Most recently, on Monday, May 23rd, Michael T. Constantino bought 2,000 shares of Humacyte stock. The stock was acquired at an average cost of $4.83 per share, with a total value of $9,660.00. Following the completion of the transaction, the director now directly owns 4,500 shares of the company's stock, valued at $21,735. Learn More on Michael T. Constantino's trading history.

Who are Humacyte's active insiders?

Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), and Laura Niklason (CEO). Learn More on Humacyte's active insiders.

Are insiders buying or selling shares of Humacyte?

During the last twelve months, insiders at the sold shares 8 times. They sold a total of 11,809,209 shares worth more than $33,429,404.91. The most recent insider tranaction occured on September, 14th when CEO Laura E Niklason sold 2,000,000 shares worth more than $5,560,000.00. Insiders at Humacyte own 23.1% of the company. Learn More about insider trades at Humacyte.

Information on this page was last updated on 9/14/2023.

Michael T. Constantino Insider Trading History at Humacyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2022Buy2,000$4.83$9,660.004,500View SEC Filing Icon  
11/22/2021Buy2,500$10.79$26,975.00View SEC Filing Icon  
See Full Table

Michael T. Constantino Buying and Selling Activity at Humacyte

This chart shows Michael T Constantino's buying and selling at Humacyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Humacyte Company Overview

Humacyte logo
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $3.90
Low: $3.71
High: $3.92

50 Day Range

MA: $3.51
Low: $2.87
High: $4.84

2 Week Range

Now: $3.90
Low: $1.96
High: $5.60

Volume

790,236 shs

Average Volume

1,122,564 shs

Market Capitalization

$464.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46